Meeting
2023 ASCO Quality Care Symposium
Results of a quality improvement program to increase complete lung cancer biomarker testing rates.
Authors
Dwight Earl Heron
Bon Secours Mercy Health, Youngstown, OH
Dwight Earl Heron, Jean Blair, Jawad Elias Francis, Kristina Stoeppler-Biege, Lijo Simpson, Jeremy Stapp, Joseph Kim
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A
Track
Quality, Safety, and Implementation Science,Cost, Value, and Policy,Patient Experience,Survivorship
Sub Track
Team-Based Approaches to Care Delivery
Citation
JCO Oncol Pract 19, 2023 (suppl 11; abstr 57)
DOI
10.1200/OP.2023.19.11_suppl.57
Abstract #
57
Poster Bd #
C10
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Identification of pretreatment genomic biomarkers and mechanisms of acquired resistance to first-line osimertinib in advanced EGFR-mutant lung cancers.
First Author: Noura J. Choudhury
Poster
2021 ASCO Annual Meeting
Sputum supernatant as a viable alternative for liquid biopsy in advanced non-small cell lung cancer.
First Author: Cheng-Zhi Zhou
Poster
2020 ASCO Virtual Scientific Program
Targeted DNA sequencing analysis to reveal genetic diversity and androgen-receptor alteration in advanced EGFR mutant lung adenocarcinoma.
First Author: Wei Wu
Poster
2017 ASCO Annual Meeting
Evolution and clinical impact of genomic alterations detectable in circulating tumor DNA of 1150 advanced EGFR-mutant (mt) lung cancer patients.
First Author: Collin M. Blakely